Trial Profile

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Oct 2024 According to a Biogen media release, complete results (n=54) were shared during an oral presentation at Kidney Week 2024, the American Society of Nephrologys annual meeting, in San Diego, California.
27 Oct 2024 Interim results presented in a Biogen Media Release.
22 Oct 2024 According to a Biogen media release, the conclusive data from this study will be presented in a late breaker oral presentation at Kidney Week 2024, the American Society of Nephrology's (ASN) annual meeting, taking place October 23-27 in San Diego, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com